Assignee
BIODESIX INC
US·41 granted patents·12 pending applications·372 citations·filing 2006–2023
Top patents by PatentIndex Score
53 records- 0198US7736905B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2006·Granted Jun 15, 2010·72 cites·18 claims
- 0296US8718996B2Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2013·Granted May 6, 2014·19 cites·10 claims
- 0395US10489550B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2017·Granted Nov 26, 2019·13 cites·7 claims
- 0495US7906342B2Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesBIODESIX INC·Filed 2009·Granted Mar 15, 2011·23 cites·3 claims
- 0595US7879620B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2010·Granted Feb 1, 2011·24 cites·8 claims
- 0695US7858389B2Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·30 cites·4 claims
- 0793US10802027B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Oct 13, 2020·6 cites·15 claims
- 0893US10007766B2Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2016·Granted Jun 26, 2018·9 cites·8 claims
- 0993US9779204B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2015·Granted Oct 3, 2017·7 cites·6 claims
- 1093US9563744B1Method of predicting development and severity of graft-versus-host diseaseBIODESIX INC·Filed 2015·Granted Feb 7, 2017·9 cites·11 claims
- 1193US9477906B2Classification generation method using combination of mini-classifiers with regularization and uses thereofBIODESIX INC·Filed 2014·Granted Oct 25, 2016·21 cites·39 claims
- 1292US10217620B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2018·Granted Feb 26, 2019·6 cites·10 claims
- 1392US9279798B2Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2013·Granted Mar 8, 2016·18 cites·21 claims
- 1492US7858390B2Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·26 cites·7 claims
- 1591US11894147B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2022·Granted Feb 6, 2024·2 cites·7 claims
- 1691US10037874B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2015·Granted Jul 31, 2018·6 cites·9 claims
- 1790US11594403B1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2018·Granted Feb 28, 2023·4 cites·11 claims
- 1890US11476003B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2021·Granted Oct 18, 2022·3 cites·10 claims
- 1990US7867775B2Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Jan 11, 2011·21 cites·5 claims
- 2089US9606101B2Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2015·Granted Mar 28, 2017·7 cites·6 claims
- 2189US9211314B2Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2014·Granted Dec 15, 2015·6 cites·30 claims
- 2288US10338074B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2016·Granted Jul 2, 2019·3 cites·13 claims
- 2387US10713590B2Bagged filtering method for selection and deselection of features for classificationBIODESIX INC·Filed 2016·Granted Jul 14, 2020·5 cites·24 claims
- 2487US9254120B2Method for predicting breast cancer patient response to combination therapyBIODESIX INC·Filed 2013·Granted Feb 9, 2016·5 cites·8 claims
- 2586US11467167B2SRM methods in Alzheimer's disease and neurological disease assaysBIODESIX INC·Filed 2019·Granted Oct 11, 2022·1 cites·16 claims
- 2685US10950348B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2018·Granted Mar 16, 2021·2 cites·11 claims
- 2784US10422729B1Blood sample separation devices and methodsBIODESIX INC·Filed 2019·Granted Sep 24, 2019·4 cites·20 claims
- 2881US8024282B2Method for reliable classification of samples in clinical diagnostics using an improved method of classificationBIODESIX INC·Filed 2008·Granted Sep 20, 2011·11 cites·34 claims
- 2979US11913957B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Feb 27, 2024·1 cites·12 claims
- 3079US11150238B2Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2018·Granted Oct 19, 2021·1 cites·8 claims
- 3177US12094587B2Apparatus and method for identification of primary immune resistance in cancer patientsBIODESIX INC·Filed 2019·Granted Sep 17, 2024·1 cites·19 claims
- 3275US11710539B2Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapyBIODESIX INC·Filed 2017·Granted Jul 25, 2023·1 cites·4 claims
- 3375US9653272B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2013·Granted May 16, 2017·2 cites·72 claims
- 3474US11621057B2Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapyBIODESIX INC·Filed 2017·Granted Apr 4, 2023·1 cites·11 claims
- 3574US10593529B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2017·Granted Mar 17, 2020·1 cites·15 claims
- 3674US2023197426A1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2023·Application pending·0 cites
- 3773US12247980B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2021·Granted Mar 11, 2025·0 cites·10 claims
- 3871US10870891B2Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole bloodBIODESIX INC·Filed 2018·Granted Dec 22, 2020·1 cites·15 claims
- 3970US12230398B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2020·Granted Feb 18, 2025·0 cites·7 claims
- 4069US2022026416A1Method for identification of cancer patients with durable benefit from immunotehrapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2021·Application pending·0 cites
- 4166US11193935B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Dec 7, 2021·0 cites·18 claims
- 4266US2021285950A1Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2020·Application pending·0 cites
- 4366US2021318320A1Calibrator for immunoassaysBIODESIX INC·Filed 2020·Application pending·0 cites
- 4465US2019056402A1Organ specific diagnostic panels and methods for identification of organ specific panel proteinsBIODESIX INC·Filed 2018·Application pending·0 cites
- 4564US10534002B2Selected reaction monitoring assaysBIODESIX INC·Filed 2017·Granted Jan 14, 2020·0 cites·12 claims
- 4659US2014200825A1Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2014·Application pending·0 cites
- 4757US2014284468A1Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samplesBIODESIX INC·Filed 2014·Application pending·0 cites
- 4855US2016019342A1Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2015·Application pending·0 cites
- 4952US2025379043A1Sensitive and accurate feature values from deep maldi spectraBIODESIX INC·Filed 2023·Application pending·0 cites
- 5050US11542340B1Antibodies targeting pulmonary nodule specific biomarkers and uses thereofBIODESIX INC·Filed 2021·Granted Jan 3, 2023·0 cites·18 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →